Sporadic Inclusion Body Myositis: At the Crossroads between Muscle Degeneration

Boel Bracke^*
*Correspondence: Boel Bracke, Department of Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy, Email:

Introduction

Sporadic Inclusion Body Myositis is a rare, progressive, and debilitating muscle disorder characterized by chronic inflammation, muscle weakness, and degeneration. Despite its low prevalence, sIBM poses significant challenges in diagnosis and treatment due to its complex pathogenesis. In recent years, research has shed light on various aspects of sIBM, revealing its intricate interplay between immune dysregulation, protein aggregation, and mitochondrial dysfunction. This article aims to explore the multifaceted nature of sIBM, emphasizing its position at the crossroads of muscle degeneration and highlighting potential therapeutic avenues [1].

The pathogenesis of sIBM involves a multifactorial interplay of immunemediated processes, protein misfolding, and mitochondrial dysfunction. Immune dysregulation plays a central role in sIBM, characterized by infiltration of CD8+ T cells and macrophages into muscle fibers, leading to chronic inflammation and muscle damage. Additionally, the accumulation of misfolded proteins, such as beta-amyloid and tau, within muscle cells contributes to the formation of inclusion bodies, further exacerbating muscle degeneration. Furthermore, impaired mitochondrial function and oxidative stress contribute to cellular dysfunction and energy depletion, exacerbating muscle weakness in sIBM [2].

Sporadic Inclusion Body Myositis typically manifests in individuals over the age of 50, presenting with insidious onset and slowly progressive muscle weakness. The weakness tends to affect proximal muscles, particularly those of the lower extremities, leading to difficulty in walking, climbing stairs, and rising from chairs. Additionally, dysphagia and dysphonia may occur due to involvement of pharyngeal and laryngeal muscles. Despite the characteristic clinical features, diagnosis of sIBM remains challenging, often requiring a combination of clinical evaluation, muscle biopsy, and laboratory investigations. The diagnosis of sIBM is complicated by its heterogeneous clinical presentation and overlapping features with other neuromuscular disorders, such as polymyositis and inclusion body myopathy. Muscle biopsy remains the gold standard for diagnosis, revealing characteristic histopathological features including rimmed vacuoles, inflammatory infiltrates, and protein aggregation within muscle fibers. However, interpretation of biopsy findings requires expertise, and false-negative results are not uncommon. Therefore, the identification of reliable biomarkers and advanced imaging techniques represents an area of active research to improve diagnostic accuracy in sIBM [3].

Description

Currently, there is no cure for sIBM, and treatment options aim to alleviate symptoms and slow disease progression. Immunosuppressive therapies, such as corticosteroids, intravenous immunoglobulin (IVIG), and immunomodulatory agents, have been employed with varying degrees of success in managing inflammation and muscle weakness. However, these treatments often provide limited benefit and may be associated with significant side effects. Emerging therapeutic approaches targeting protein misfolding, mitochondrial dysfunction, and immune dysregulation offer promise in sIBM management. Strategies including proteostasis modulators, mitochondrial-targeted therapies, and biologic agents directed against specific immune pathways represent areas of active investigation [4].

The elucidation of sIBM pathogenesis and the identification of potential therapeutic targets have paved the way for innovative treatment strategies. However, further research is needed to optimize diagnostic methods, develop reliable biomarkers, and conduct clinical trials to evaluate the efficacy of novel therapies. Collaborative efforts involving clinicians, researchers, and patient advocacy groups are essential to advance our understanding of sIBM and improve outcomes for affected individuals [5].

Conclusion

Sporadic Inclusion Body Myositis represents a complex neuromuscular disorder characterized by immune dysregulation, protein aggregation, and mitochondrial dysfunction. Despite significant progress in unraveling its pathogenesis, sIBM remains challenging to diagnose and treat. The development of targeted therapeutic interventions holds promise in mitigating muscle degeneration and improving quality of life for individuals living with sIBM. Continued research efforts are imperative to address the unmet needs of patients and ultimately find a cure for this debilitating condition.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Engel, W. King and Valerie Askanas. "Inclusion-body myositis: Clinical, diagnostic, and pathologic aspects."Neurology66 (2006): S20-S29.

   Google Scholar, Crossref, Indexed at

2. Carpenter, Stirling, George Karpati, Irving Heller and Andrew Eisen. "Inclusion body myositis: A distinct variety of idiopathic inflammatory myopathy."Neurology28 (1978): 8-8.

   Google Scholar, Crossref, Indexed at

3. Price, Mark A., Victoria Barghout, Olivier Benveniste and Lisa Christopher-Stine, et al. "Mortality and causes of death in patients with sporadic inclusion body myositis: Survey study based on the clinical experience of specialists in Australia, Europe and the USA."J Neuromuscul Dis 3 (2016): 67-75.

   Google Scholar, Crossref, Indexed at

4. Needham, Merrilee, Alastair Corbett, Timothy Day and Frank Christiansen, et al. "Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis."J Clin Neurosci 15 (2008): 1350-1353.

   Google Scholar, Crossref, Indexed at

5. Callan, Aoife, Gorana Capkun, Vijayalakshmi Vasanthaprasad and Rita Freitas, et al. "A systematic review and meta-analysis of prevalence studies of sporadic inclusion body myositis."J Neuromuscul Dis 4 (2017): 127-137.

   Google Scholar, Crossref, Indexed at